MNG320
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.273
- HEDGEHOG_SIGNALING+0.223
- ANDROGEN_RESPONSE+0.214
- WNT_BETA_CATENIN_SIGNALING+0.210
- INTERFERON_ALPHA_RESPONSE+0.206
- APICAL_SURFACE+0.106
- TGF_BETA_SIGNALING+0.099
- ESTROGEN_RESPONSE_EARLY+0.098
- PEROXISOME+0.078
- MITOTIC_SPINDLE+0.076
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.510
- TNFA_SIGNALING_VIA_NFKB-0.377
- ANGIOGENESIS-0.357
- E2F_TARGETS-0.338
- GLYCOLYSIS-0.327
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.327
- MYC_TARGETS_V2-0.312
- G2M_CHECKPOINT-0.309
- UV_RESPONSE_UP-0.304
- INFLAMMATORY_RESPONSE-0.296
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG288 | — | — | 0.847 |
| 2 | MNG842 | — | — | 0.821 |
| 3 | MNG526 | — | — | 0.820 |
| 4 | SRR661005 | GTEX | — | 0.807 |
| 5 | MDT-AP-3267 | Med | Medulloblastoma | 0.800 |
| 6 | MNG961 | — | — | 0.797 |
| 7 | TCGA-69-7764-01A-11R-2170-07 | — | cohortA2 | 0.795 |
| 8 | C3N-00293 | — | cohortA1 | 0.794 |
| 9 | SRR8526730 | — | cohortA1 | 0.793 |
| 10 | SRR1313106 | — | B | 0.793 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.273 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.223 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.214 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.206 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.106 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.099 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.098 | Inavolisib | — uncovered |
| PEROXISOME | 0.078 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.076 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.064 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.041 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.033 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.026 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.005 | Remibrutinib | — uncovered |